^
    Back
    Association details:
    Biomarker:Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
    Cancer:Acute Myelogenous Leukemia
    Regimen: (cladribine + cytarabine + Neupogen (filgrastim))
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment

    Published date:
    02/08/2022
    Excerpt:
    Case 1 is a 33-year-old female diagnosed with AML. Her karyotype was 45, X, -X, t(8;21)(q22;q22) (8)/46, XX, idem (2), AML1-ETO was 39700 copies/10000 abl copies (AML1-ETO transcripts were normalized to 104 abl copies), and KIT exon 17 and CSF3R mutations were detected...the disease relapsed, and she failed to achieve CR again after salvage chemotherapy with CLAG (cladribine 5 mg/m2 d1-5, cytarabine 2 mg/m2 d1-5, G-CSF 5 μg/kg d0-5).
    DOI:
    https://doi.org/10.3389/fonc.2022.841276